{"id":"https://openalex.org/W3213698120","doi":"https://doi.org/10.1182/blood-2021-153855","title":"MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma","display_name":"MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma","publication_year":2021,"publication_date":"2021-11-05","ids":{"openalex":"https://openalex.org/W3213698120","doi":"https://doi.org/10.1182/blood-2021-153855","mag":"3213698120"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2021-153855","doi":"https://doi.org/10.1182/blood-2021-153855","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-153855","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014612024","display_name":"Madhav Rao Seshadri","orcid":"https://orcid.org/0000-0001-5106-1979","observed_orcids":["https://orcid.org/0000-0001-5106-1979"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Madhav R Seshadri","raw_affiliation_strings":["Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075804980","display_name":"Lorena Font\u00e1n","orcid":"https://orcid.org/0000-0002-1021-3654","observed_orcids":["https://orcid.org/0000-0002-1021-3654"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lorena Fontan","raw_affiliation_strings":["Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075938511","display_name":"Prasanna Sreevatsan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Prasanna Sreevatsan","raw_affiliation_strings":["Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA","Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005583868","display_name":"David A. Scott","orcid":"https://orcid.org/0000-0003-3243-528X","observed_orcids":["https://orcid.org/0000-0003-3243-528X"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Scott","raw_affiliation_strings":["Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA","Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012615258","display_name":"John M. Hatcher","orcid":"https://orcid.org/0000-0002-3540-7842","observed_orcids":["https://orcid.org/0000-0002-3540-7842"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Hatcher","raw_affiliation_strings":["Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA","Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Guangyan Du","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guangyan Du","raw_affiliation_strings":["Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA","Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082858747","display_name":"Min Xia","orcid":"https://orcid.org/0000-0002-1093-5008","observed_orcids":["https://orcid.org/0000-0002-1093-5008"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Min Xia","raw_affiliation_strings":["Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014192350","display_name":"Ilkay Us","orcid":"https://orcid.org/0000-0003-4573-0210","observed_orcids":["https://orcid.org/0000-0003-4573-0210"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ilkay Us","raw_affiliation_strings":["Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022352605","display_name":"Nathanael S. Gray","orcid":"https://orcid.org/0000-0001-5354-7403","observed_orcids":["https://orcid.org/0000-0001-5354-7403"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nathanael Gray","raw_affiliation_strings":["Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA","Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019770989","display_name":"Ari M. Melnick","orcid":"https://orcid.org/0000-0002-8074-2287","observed_orcids":["https://orcid.org/0000-0002-8074-2287"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ari Melnick","raw_affiliation_strings":["Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY","institution_ids":["https://openalex.org/I4387153466"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"Supplement 1","first_page":"269","last_page":"269"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11591","display_name":"NF-\u03baB Signaling Pathways","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/malt1","display_name":"MALT1","score":0.9210000038146973},{"id":"https://openalex.org/keywords/protacs","display_name":"PROTACs","score":0.8349999785423279},{"id":"https://openalex.org/keywords/abc-dlbcl","display_name":"ABC-DLBCL","score":0.8420000076293945},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9330000281333923},{"id":"https://openalex.org/keywords/nf-kappab-signaling","display_name":"NF-\u03baB signaling","score":0.8080000281333923},{"id":"https://openalex.org/keywords/cereblon","display_name":"cereblon","score":0.6449999809265137},{"id":"https://openalex.org/keywords/immunomodulators","display_name":"immunomodulators","score":0.6639999747276306},{"id":"https://openalex.org/keywords/ubiquitination","display_name":"ubiquitination","score":0.6949999928474426},{"id":"https://openalex.org/keywords/proteasomal-degradation","display_name":"proteasomal degradation","score":0.8240000009536743},{"id":"https://openalex.org/keywords/ikappab-degradation","display_name":"I\u03baB degradation","score":0.6259999871253967}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5124250054359436},{"id":"https://openalex.org/C2781307694","wikidata":"https://www.wikidata.org/wiki/Q33123","display_name":"Proteolysis","level":3,"score":0.4746706485748291},{"id":"https://openalex.org/C2776714187","wikidata":"https://www.wikidata.org/wiki/Q212410","display_name":"Protease","level":3,"score":0.4713696241378784},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.4583541452884674},{"id":"https://openalex.org/C53645450","wikidata":"https://www.wikidata.org/wiki/Q907093","display_name":"Scaffold protein","level":3,"score":0.44520658254623413},{"id":"https://openalex.org/C2992195973","wikidata":"https://www.wikidata.org/wiki/Q33123","display_name":"Protein degradation","level":2,"score":0.4280935525894165},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.4280293583869934},{"id":"https://openalex.org/C2778453870","wikidata":"https://www.wikidata.org/wiki/Q188930","display_name":"B cell","level":3,"score":0.42071861028671265},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.4002719521522522},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.37802398204803467},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.30547595024108887},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.23879283666610718},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22435086965560913},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.18219491839408875},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.14520975947380066},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.1346854269504547}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2021-153855","doi":"https://doi.org/10.1182/blood-2021-153855","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-153855","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3176164717","https://openalex.org/W2984487370","https://openalex.org/W3213865486","https://openalex.org/W2551584161","https://openalex.org/W2139792086","https://openalex.org/W2951693818","https://openalex.org/W1910594103","https://openalex.org/W4405126159","https://openalex.org/W2810730310","https://openalex.org/W2540213618"],"abstract_inverted_index":{"Abstract":[0],"Introduction":[1],"ABC-DLBCL":[2,341,382,600],"is":[3,11,52,63,76,83,239,283,423,627],"characterized":[4],"by":[5,70,219,285,306],"chronic":[6,366],"activation":[7,43,264,368,589],"of":[8,113,131,138,146,172,180,194,207,236,322,381,421,436,573,577,584,599,618,654,674,685,696,707,718,729,740,751,762,773,785,840],"NF\u03baB,":[9],"which":[10,111,125,238,279,569],"dependent":[12,364],"on":[13,365,425,438,638,781,836],"the":[14,273,419,434],"CARD11-BCL10-MALT1":[15],"(CBM)":[16],"complex.":[17],"MALT1":[18,31,45,50,80,87,154,181,242,258,261,268,286,323,426,466,574,585,592,621,643,655],"activates":[19],"NF\u03baB":[20,42,237,263,367,588],"transcription":[21],"factors":[22],"via":[23,44],"distinct":[24,636],"protease":[25,32,51,88,269,324,593,644],"and":[26,60,128,170,226,313,342,355,369,458,473,607,633,657],"scaffold":[27,46,92,243,586],"functions.":[28],"Clinical":[29],"allosteric":[30,465,497,556],"inhibitors":[33],"are":[34,362,648],"in":[35,247,278,288,483,605,610,661,677,688,699,710,721,732,743,754,765,776],"development,":[36],"however":[37],"these":[38],"agents":[39],"partially":[40],"preserve":[41],"function.":[47],"In":[48],"addition,":[49],"critical":[53],"for":[54,149,167,215,223,302,310,352,468,540],"regulatory":[55],"T":[56,439,443,515,528,552],"cell":[57,173,344,383,405,440,601],"(Treg)":[58],"function,":[59],"its":[61],"inactivation":[62],"associated":[64],"with":[65,79,90,161,213,221,298,308,348,455,460,492,536,575],"increased":[66,232],"inflammatory":[67],"cytokine":[68],"expression":[69],"T-effector":[71,639],"cells.":[72,562,613],"However,":[73],"overt":[74],"inflammation":[75],"not":[77,363,559],"seen":[78],"knockout.":[81],"It":[82],"therefore":[84],"possible":[85],"that":[86,257,620],"inhibition":[89,321,380,598],"preserved":[91],"function":[93],"will":[94],"lead":[95,140],"to":[96,118,143,254,327,372,375,500,544,642,650,658],"autoimmune":[97],"toxicities.":[98],"As":[99],"an":[100,119,234,464,782,837],"alternative":[101],"strategy,":[102],"we":[103,134,209,271],"developed":[104],"MALT1-directed":[105,567],"proteolysis":[106],"targeting":[107],"chimera":[108],"(PROTAC)":[109],"compounds":[110],"consist":[112],"a":[114,139,280,480,566,624,628,678,689,700,711,722,733,744,755,766,777],"MALT1-binding":[115],"domain":[116],"linked":[117],"IMiD-based":[120],"cereblon":[121],"(CRBN)":[122],"binding":[123],"domain,":[124],"induce":[126],"ubiquitination":[127],"proteasomal":[129],"degradation":[130,179,193,259,572,622,656],"MALT1.":[132],"Here":[133],"present":[135],"preliminary":[136],"studies":[137,647],"compound,":[141],"PS-II-115,":[142,462],"assess":[144,153,204,338],"feasibility":[145],"this":[147,294],"approach":[148],"ABC-DLBCL.":[150],"Results":[151],"To":[152,203,266,337],"protein":[155,282],"degradation,":[156],"OCI-Ly3":[157,211],"cells":[158,212,250,292,444,490,529,534],"were":[159,175,228,296,346,370,445,453],"treated":[160,210,249,297,347,459,491,535],"DMSO":[162,299,328,349,501,510,545],"or":[163,199,300,350,463,470,496,787,842],"PS-II-115":[164,177,214,248,301,318,351,377,422,437,493,537],"10":[165],"\u00b5M":[166,495,539],"24":[168],"hours":[169,217,304,472,504,542],"immunoblots":[171,227],"lysates":[174],"performed.":[176,229,317,360,477],"induced":[178,319,378],"(degradation":[182],"\u00b1SEM":[183],"73.94":[184],"\u00b19.8%":[185],"vs":[186,547],"DMSO,":[187,461],"N":[188],"=":[189],"3).":[190],"No":[191],"significant":[192,481],"CRBN":[195,580],"neosubstrates":[196],"IKZF1,":[197],"IKZF3,":[198],"GSPT1":[200],"was":[201,316,359,476],"seen.":[202],"effects":[205,637,653],"downstream":[206],"MALT1,":[208],"23.5":[216,303],"followed":[218,305],"stimulation":[220,307],"PMA/IO":[222,309],"30":[224,311],"minutes,":[225,312],"We":[230,431,478,518,564],"found":[231,479,520],"I\u03baB,":[233],"inhibitor":[235,467,498,557],"degraded":[240],"following":[241],"mediated":[244,587],"IKK":[245],"activation,":[246],"(IkB":[251],"206%":[252],"compared":[253,326,499,543,641],"DMSO),":[255],"suggesting":[256,418],"inhibits":[260],"scaffold-mediated":[262],"pathways.":[265],"measure":[267],"inhibition,":[270,340,594],"used":[272],"GloSensor":[274,314],"split":[275],"luciferase":[276],"method,":[277],"chimeric":[281],"cleaved":[284],"resulting":[287],"functional":[289],"luciferase.":[290],"Raji":[291],"expressing":[293,530],"construct":[295],"assay":[315,358],"dose-dependent":[320],"activity":[325],"(IC":[329],"50":[330,387,392,397,409,414],"1.203":[331],"\u00b5M,":[332,389,394,399,411,416],"95%":[333],"CI":[334],"0.374-4.230,":[335],"N=4).":[336],"growth":[339,379,597],"GCB-DLBCL":[343,404],"lines":[345,384,406],"96":[353,471,541],"hours,":[354],"CellTiter":[356],"Glo":[357],"GCB-DLBCLs":[361],"expected":[371],"be":[373],"resistant":[374],"PS-II-115.":[376],"(OCI-Ly3":[385],"IC":[386,391,396,408,413],"2.54":[388],"OCI-Ly10":[390],"9.65":[393],"TMD8":[395],"1.87":[398],"N=4)":[400],"more":[401],"potently":[402],"than":[403,428],"(OCI-Ly1":[407],"34.6":[410],"OCI-Ly7":[412],">50":[415],"N=4),":[417],"effect":[420],"based":[424],"rather":[427],"off-target":[429],"effects.":[430],"then":[432],"assessed":[433],"impact":[435],"phenotypes.":[441],"Human":[442],"isolated":[446],"from":[447],"healthy":[448],"donors'":[449],"peripheral":[450],"blood.":[451],"Cells":[452],"stimulated":[454],"CD3/CD28":[456],"beads":[457],"48":[469,503],"flow":[474],"cytometry":[475],"decrease":[482,604,609],"CD4+":[484,514,523,551,611],"FOXP3+":[485],"CD25+":[486],"CD127-":[487],"Tregs":[488,512],"among":[489,513,533,550],"1":[494],"at":[502],"(PS-II-115":[505],"3.89%,":[506],"allo":[507],"inh":[508],"3.85%,":[509],"9.72%":[511],"cells,":[516,553],"P<0.005).":[517],"also":[519],"decreased":[521],"pro-inflammatory":[522],"CD45RA+":[524],"CCR7-":[525],"terminal":[526],"effector":[527],"RA":[531],"(TEMRA)":[532],"20":[538],"(35.67%":[546],"56.97%":[548],"TEMRA":[549,561,612],"p<0.05).":[554],"The":[555],"did":[558],"affect":[560],"Conclusion":[563],"describe":[565],"PROTAC":[568,625],"induces":[570],"(1)":[571],"preservation":[576],"other":[578],"IMiD-associated":[579],"neosubstrates,":[581],"(2)":[582],"blockade":[583],"pathways,":[590],"(3)":[591],"(4)":[595],"selective":[596],"lines,":[602],"(5)":[603],"Tregs,":[606],"(6)":[608],"These":[614],"results":[615],"provide":[616],"proof":[617],"principle":[619],"using":[623],"compound":[626],"feasible":[629],"strategy":[630],"against":[631],"ABC-DLBCL,":[632],"may":[634],"have":[635],"phenotypes":[640],"inhibition.":[645],"Further":[646],"needed":[649],"elucidate":[651],"immunologic":[652],"validate":[659],"findings":[660],"vivo.":[662],"Disclosures":[663],"Fontan:":[664],"Janssen":[665,829],"Pharmaceuticals:":[666,830],"Current":[667,672,683,694,705,716,727,738,749,760,771],"Employment.":[668],"Gray:":[669],"Gatekeeper:":[670],"Consultancy,":[671,682,693,704,715,726,737,748,759,770],"holder":[673,684,695,706,717,728,739,750,761,772],"individual":[675,686,697,708,719,730,741,752,763,774],"stocks":[676,687,698,709,720,731,742,753,764,775],"privately-held":[679,690,701,712,723,734,745,756,767,778],"company;":[680,691,702,713,724,735,746,757,768],"Syros:":[681],"Petra:":[692],"C4:":[703],"Allorion:":[714],"Jengu:":[725],"B2S:":[736],"Inception:":[747],"EcoCys:":[758],"Soltego:":[769],"company,":[779],"Membership":[780,835],"entity's":[783,838],"Board":[784,839],"Directors":[786,841],"advisory":[788,843],"committees;":[789],"Novartis:":[790],"Research":[791,794,797,800,803,806,809,812,815,824,827,831],"Funding;":[792,795,798,801,804,807,810,813,825,828,832],"Takeda:":[793],"Astellas:":[796],"Taiho:":[799],"Janssen:":[802],"Kinogen:":[805],"Her2IIc:":[808],"Deerfield:":[811],"Sanofi:":[814,826],"Funding.":[816],"Melnick:":[817],"Constellation:":[818],"Consultancy;":[819,821],"Epizyme:":[820],"Daiichi":[822],"Sankyo:":[823],"KDAC":[833],"Pharma:":[834],"committees.":[844]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2021-11-22T00:00:00"}